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Abstract 
 In this research, I focused on the signal transducer and activator of transcription 6 
(STAT6) signal in two different pathways of various immune cell types—the 
interferon-4 (IL-4)/interferon-13 (IL-13) activating pathway in Th2 cells and the DNA 
virus activating pathway in dendritic cells. IL-4 and STAT6 mediate Th2 responses in T 
cells and immunoglobulin class switching to IgE in B cells, thus regulating the balance 
between inflammatory and allergic immune responses. On the other hand, the DNA 
virus activating pathway in dendritic cells initiates the transcription of genes encoding 
chemokines such as chemokine (C-C motif) ligand 2 (CCL2) and chemokine (C-C 
motif) ligand 20 (CCL20). These chemokines especially enhance tumor specific 
immunity, presumably in a T-lymphocyte-dependent manner, and STAT6 signaling can 
play an important role in tumor immunity. Poly (ADP-ribose) polymerase 14 (PARP14) 
and DEAD-Box helicase 41 (DDX41) are promising molecular targets of drug 
discovery related to STAT6. In this stury, I biochemically characterized these two 
enzymes and identified their selective inhibitors by high-throughput screening (HTS).  
The enzymes related to STAT6, PARP14, and DDX41, were evaluated by 
enzymological analysis. First, novel assay methods were established for evaluating the 
autoribosylation activity of PARP14 using HTMS and immunoradiometric assay. 
Through these assays, HTS was conducted using a library of more than 500,000 
compounds and hit compounds were identified. The co-crystallization of PARP14 and 
some of the hit compounds revealed that the inhibitors interacted with the nicotinamide 
adenine dinucleotide (NAD
+
)-binding site of PARP14. Finally, I confirmed that the 
identified hit compounds were able to interact with intracellular PARP14 using a 
cell-based protein stabilization assay. Thus, primary candidate compounds were 
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successfully identified. Secondly, I clarified that the ATPase activities of human DDX41 
and R525H are dependent on ATP and dsDNA, either through poly(dG–dC) or 
poly(dA–dT). Novel inhibitors of DDX41 and R525H were identified by HTS. Hit 
compounds with selective inhibitory activities were identified using several assays. 
These results provide an ideal platform for the discovery of PARP14 and DDX41 
inhibitors, present new chemical tools for use in investigating the multiple functions of 
these enzymes, and open a new horizon for drug discovery research related to STAT6 
signaling. 
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Abbreviations 
AML  acute myeloid leukemia  
BCR  B cell receptor . 
CCL  chemokine (C-C motif) ligand  
DDX41  DEAD-Box Helicase 41 
DTT  dithiothreitol  
E. coli  Escherichia coli 
HIPK2  delta-1Homeodomain Interacting Protein Kinase 2 
HTMS  high throughput mass spectrometry  
HTS  high-throughput screening  
IC50  50% inhibitory concentrations 
IFNs  interferons  
IRF3  interferon regulatory factor 3  
JAK  janus kinase  
MDS  myelodysplastic syndrome 
NAD
+
  nicotinamide adenine dinucleotide  
NF-κB  nuclear factor-kappa B 
PARP14  poly (ADP-ribose) polymerase 14 
PARP14−/−   poly (ADP-ribose) polymerase 14 knockout  
PARPs  poly(ADP-ribose) polymerases 
PCR  polymerase chain reaction  
PLCD1  phospholipase C, delta-1 
R525H  R525H mutant 
RORγ  retineic acid receptor related orphan nuclear γ 
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Runx3  runt related transcription factor 3 
SD  standard deviation 
SDS-PAGE  sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
STAT  signal transducer and activator of transcription  
STING  stimulator of interferon genes 
TBK1  TANK-binding kinase 1 
TCR  T cell receptor  
Treg regulatory T cells 
WT  wild type 
dsDNA  double-stranded DNA  
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General Introduction 
 Immune system and immune responses 
Organisms often encounter pathogens like bacteria or viruses that cause potentially 
harmful disease. However, they can function properly and live without constantly being 
sick in most cases because organisms like humans have a multilayered immune system 
to keep it running without difficulties. Immune responses are mainly categorized into 
innate immunity and adaptive immunity as shown in Fig. 1 and Table 1 [1, 2].  
 
 
Figure 1. Interactions of innate and adaptive immunity.  
  
Innate immune responses are mediated by leukocytes, macrophages, and dendritic 
cells, which are collectively called phagocytes because they engulf and kill microbes. In 
the case of dendritic cells, they have an additional role of presenting antigenic peptides 
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derived from microbes to T cells [3]. Dendritic cells engulf pathogens, digest them into 
small peptides, and express the peptide antigens on their cell surface. The dendritic cells 
then migrate from the infected tissue to the regional lymph nodes, where they present 
the antigens to naive T cells with parallel receptors. Cells in the innate immune system 
recognize and respond to pathogens discriminating by self from foreign pathogens. 
Although the innate immune system is an immediate defense against infection, it is a 
temporary system until adaptive immune responses can be triggered. In higher 
metazoans such as vertebrates, adaptive immune responses occur in addition to innate 
immune responses.  
Table 1 Innate and adaptive immunity 
  Innate immune system Adaptive immune system 
Property Fixed in genome Encoded in gene segments 
Receptors Rearrangement is not necessary Rearrangement necessary 
Distribution Non-clonal Clonal 
  All cells of a class identical All cells of a class distinct 
Recognition Conserved molecular patterns Details of molecular structure 
  (LPS, LTA, mannans, glycans) (proteins, peptides, carbohydrates) 
Self-Non-self 
discrimination 
Perfect: selected over evolutionary 
time 
Imperfect: selected in individual 
somatic cells 
Action time Immediate activation of effectors  Delayed activation of effectors 
Response 
Co-stimulatory molecules Clonal expansion or anergy 
Cytokines (IL-1β, IL-6) IL-2 
Chemokines (IL-8) Effector cytokines: (IL-4, IFN-γ) 
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Adaptive immunity is activated by exposure to pathogens, and uses immunological 
memory to learn about the threat and enhance the immune response unlike the innate 
immune system. The adaptive immune response is much slower to respond to threats 
and infections compared to the innate immune response as shown in Table 1, and 
functions through B cells and T cells. Both cells are lymphocytes derived from specific 
types of multipotent hematopoietic stem cells in the bone marrow. After they are made 
in the bone marrow, they are matured and activated. Each cell type follows a different 
path to attain the mature form.  
In the lymphatic system, maturation of B cells begins when naïve B cells encounter 
an antigen [4-6]. Naïve B cells express one of millions of distinctive antibodies on their 
cell surface, which can also be called membrane-bound antibodies. When a naïve B 
cells encounters an antigen that can react with its membrane-bound antibody, it quickly 
divides in order to become either a memory B cell or plasma B cell. Memory B cells 
produce antibodies only upon re-stimulation by the specific antigen and their response 
in conferring protection against reinfection has remained controversial. Plasma B cells 
secrete antibodies to protect from infection. The secreted antibodies identify free 
pathogens circulating throughout the body. B cells also express a specialized receptor 
called the B cell receptor (BCR). BCRs assist with antigen binding, as well as 
internalization and processing of the antigen. After the antigen is internalized and 
processed, the B cell can initiate signaling pathways such as cytokine release and 
communicate with other cells of the immune system. 
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Figure 2 Differentiation of naïve CD4+ T cells into Tregs or effector T cells 
 
T cells also have important roles in the adaptive immune system. Once formed in the 
bone marrow, T progenitor cells migrate to the thymus for maturation and become T 
cells. The developing T cells express T cell receptors (TCRs), and either CD4 or CD8 
receptors in the thymus [7, 8]. TCRs recognize antigens that are bound to certain 
receptor molecules and undergo a process called rearrangement, resulting in nearly 
limitless recombination of a gene that encodes antibodies. Naïve CD4+ T cells can be 
differentiated into regulatory T cells (Tregs) or effector T cells shown in Fig. 2. The 
transcription factors T-bet and runt related transcription factor 3 (Runx3), GATA3, or 
retinoic acid receptor related orphan nuclear γ (ROR-γ) are required for the 
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differentiation of naive T cells into Th1, Th2, or Th17 cells, respectively. Mature T cells 
should recognize only foreign antigens in order to mount an appropriate immune 
response and secrete specific cytokines (Table 2).  
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Table 2 Examples of cytokines and primary activities 
 
Cytokines Principal Source Primary Activity
GM-CSF  Th cells Growth and differentiation of monocytes and dendritic cells
IL-1α Macrophages and other antigen
IL-β presenting cells (APCs)
IL-2 Activated Th1 cells, NK cells Proliferation of B cells and activated T cells, NK functions
IL-3 Activated T cells Growth of hematopoietic progenitor cells
IL-4 Activated T cells
B cell proliferation, eosinophil and mast cell growth and
function, IgE and class II MHC, expression on B cells,
inhibition of monokine production
IL-5 Th2 and mast cells Eosinophil growth and function
IL-6
Activated Th2 cells, APCs, other
somatic cells
Acute phase response, B cell proliferation, thrombopoiesis,
synergistic with IL-1 and TNF on T cells
IL-7 Thymic and marrow stromal cells T and B lymphopoiesis
IL-8 macrophages, somatic cells Chemoattractant for neutrophils and T cells
IL-9 T cells Hematopoietic and thymopoietic effects
IL-10
Activated Th2 cells, CD8+ T and
B cells, macrophages
Inhibits cytokine production, promotes B cell proliferation
and antibody production, suppresses cellular immunity,
mast cell growth
IL-11 Atromal cells Synergistic hematopoietic and thrombopoietic effects
IL-12 B cells, macrophages
Proliferation of NK cells, IFN production, promotes cell-
mediated immune functions
IL-13 Th2 cells IL-4-like activities
IL-18 Macrophages potent inducer of interferon-+ by T cells and NK cells
IFN-α
IFN-β
IFN-γ Activated Th1 and NK cells
Induces of class I MHC on all somatic cells, induces class II
MHC on APCs and somatic cells, activates macrophages,
neutrophils, NK cells, promotes cell-mediated immunity,
antiviral effects
MIP-1α Macrophages Chemotaxis
MIP-1β Lymphocytes Chemotaxis
TGF-β T cells, monocytes
Chemotaxis, IL-1 synthesis, IgA synthesis, inhibit
proliferation
TNF-α 
macrophages, mast cells, NK cells,
sensory neurons
Cell death, inflammation, pain
TNF-β Th1 and Tc cells phagocytosis, NO production, cell death
Costimulation of APCs and T cells, inflammation and fever,
acute phase response, hematopoiesis
Macrophages, neutrophils and
some somatic cells
Antiviral effects, induction of class I MHC on all somatic
cells, activation of NK cells and macrophages
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STAT pathways activated by cytokines 
Cytokines are small secreted proteins released by cells. They have a specific effect on 
the interactions and communications between immune cells [9, 10]. Cytokine is a 
general name; other names include lymphokine, monokine, chemokine, and interleukin 
(IL). Cytokines may react with the cells that secrete them, with nearby cells, or in some 
instances, with distant cells. They are often produced in a cascade, as one cytokine 
stimulates its target cells to express additional cytokines. Cytokines exert their functions 
by binding to specific cellular receptors; therefore both cytokine and receptor 
expression can determine the nature of an individual cell response, and in a broader 
context, it can impact on the intensity and duration of the inflammatory response, 
ultimately affecting the clinical outcome of periodontal/periapical disease [9]. 
 
 
Figure 3 A schematic representation of STAT proteins 
 
Some cytokines, including ILs, interferons (IFNs), and hematopoietic growth factors, 
activate Janus kinase (JAK)/signal transducers and activators of transcription (STAT) 
pathway [11-13]. STAT proteins comprise seven members: STAT1, STAT2, STAT3, 
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STAT4, STAT5A, STAT5B, and STAT6 (Fig. 3). These share five domains structurally, 
which include an amino-terminal domain, a coiled-coil domain, a DNA-binding domain, 
an SH2 domain, and a carboxy‑terminal transactivation domain. Activation of STAT is 
promoted as shown in Fig. 4, when ligands such as cytokines bind their receptors 
expressed on the cellular membrane. The cytokine-receptor interaction induces receptor 
phosphorylation, which recruits STAT proteins to the phospho-motifs of the receptor. 
Phosphorylation of the critical tyrosine residue in STAT proteins is then initiated by 
tyrosine kinases, such as growth factor receptors, JAKs (JAK1, JAK2, JAK3, and Tyk2), 
and SRC family kinases [14]. Phosphorylation of a tyrosine residue present in the trans 
activation domain and two phosphorylated STAT monomers dimerize through reciprocal 
pTyr‑SH2 domain interactions, and these STAT–STAT dimers translocate to the nucleus 
where they bind to specific STAT-response elements in the target gene promoters and 
regulate transcription. STAT-dependent induction of genes is essential for many 
physiological functions. Activation of normal STAT signals is controlled by 
physiologically negative modulators such as suppressors of cytokine signals and protein 
tyrosine phosphatases, in accordance with normal cellular functions. Although STAT 
proteins are differentially activated and promote varying cellular processes depending 
on the ligand and cell types, their normal induction collectively regulates cell growth, 
differentiation, survival, and apoptosis. Such inductions lead to regulation of 
inflammatory and immune responses, embryonic development, and mammary gland 
development. On the other hand, defective or abnormal STAT signaling is associated 
with various human diseases including susceptibility to infection, immune disorders, 
many types of cancer, asthma, and allergic diseases. Therefore, STAT signaling is one of 
the important signals to control human diseases. 
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Figure 4 STAT signal pathway 
 
Some studies have indicated that STAT6 signaling plays a predominant role in the 
immune system. STAT6 signaling was shown to be present in two different pathways in 
various cell types (Fig. 5): the IL-4/IL-13 activating pathway and the DNA virus 
activating pathway [15]. IL-4 induces the phosphorylation of IL-4 receptor, which in 
turn recruits cytosolic STAT6 by its SH2 domain; the recruited STAT6 is 
phosphorylated at tyrosine 641 (Y641) by JAK1, which results in its dimerization and 
nuclear translocation to activate the target genes [16-19]. Some of the STAT6-bound 
regions coincide with various epigenetic marks, and the corresponding genes include 
IL-4, GATA3, IL-24, phospholipase C, delta-1(PLCD1), and homeodomain interacting 
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protein kinase 2 (HIPK2). This leads to Th2 polarization. IL-4 and STAT6 mediate Th2 
responses in T cells and immunoglobulin class switching to IgE in B cells, thus 
regulating the balance between inflammatory and allergic immune responses [20-23]. 
Therefore IL-4 and STAT6 signaling is an attractive therapeutic target pathway. To date, 
various studies on discovering the modulators of STAT6 signaling have been reported. 
Some peptides, small molecules, or natural products are reported to inhibit STAT6 
dimerization, whereas some small molecules are reported to inhibit JAK1 that 
phosphorylates STAT6. However, these inhibitors show weak activities against STAT6 
protein or nonspecific activities against JAK1 even if the compounds possess high 
activity. Therefore, discovery of promising novel molecular targets in IL-4 and STAT6 
signaling has been desired. Previous studies indicate that poly (ADP-ribose) polymerase 
14 (PARP14) enhances IL-4-induced gene expression by interacting with the cytokine 
induced signal transducer as an activator of STAT6 in B and T cells. In the absence of 
IL-4, PARP14 binds to STAT6 responsive promoters, and functions as a transcriptional 
repressor by recruiting HDAC2, HDAC3, and p100 co-factor. On the other hand, 
PARP14 is replaced in the presence of IL-4 and transcription of STAT6 responsive 
genes is initiated. Therefore, PARP14 is required for STAT6-dependent gene expression. 
Moreover, some biological experiments have shown that inhibition of PARP14 possibly 
prohibits STAT6-related diseases [24, 25]. These studies indicate that PARP14 is an 
enzyme modulating the IL4 and STAT6 signaling and that PARP14 can be a more 
suitable drug target molecule compared to STAT6 or JAK, because some inhibitors of 
PARP1, which belongs to the PARP family similar to PARP14, have been reported and 
showed selective and high inhibitory activities against PARP1[26-28].  
On the other hand, DNA virus infection triggers STAT6 activation in some immune 
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cells such as dendritic cells [29, 30]. Stimulator of interferon genes (STING), which 
plays a central role in integrating signals from DNA virus infection, is activated by 
DNA virus infection and then recruits STAT6. TANK-binding kinase 1 (TBK1) is also 
recruited by STING to phosphorylate STAT6 on S407, which in turn activates another 
unidentified tyrosine kinase to phosphorylate STAT6 on Y641, leading to the 
homodimerization and nucleus translocation of STAT6. The STAT6 dimer then binds to 
its target sites to initiate the transcription of genes encoding chemokines such as CCL2 
and CCL20. These chemokines especially enhance tumor specific immunity, 
presumably in a T-lymphocyte dependent manner indicating that this STAT6 signal can 
play an important role in tumor immunity [31, 32]. Research efforts to discover 
molecules to modulate STING are still ongoing in the field of STAT6 signaling. On the 
other hand, obtaining small molecules with activities against STING is considered 
difficult because the number of reported small molecules against STING is extremely 
small despite its popularity. The reported agonists and antagonists are mainly 
compounds like cyclic dinucleotides. Recently, DEAD-Box Helicase 41 (DDX41) was 
discovered as a molecule that modulates STAT6 signaling in accordance with STING 
[33, 34]. Moreover, a comprehensive genetic analysis identified a somatic mutation in 
DDX41, which was shown to be a cause of the familial acute myeloid leukemia 
(AML)/myelodysplastic syndrome (MDS) pedigree.  
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Figure 5 Two different pathways in STAT6 signaling 
 
In this thesis, I have described my studies focusing on PARP14 and DDX41 as 
significant molecules in STAT6 signaling. It was revealed that these enzymes might 
play an important role in STAT6- related diseases. However, very little is known about 
the biochemical properties of these enzymes even though some biological experiments 
have been reported. Thus, I biochemically characterized these enzymes and identified 
selective inhibitors against these enzymes by high-throughput screening (HTS).  
In the first chapter, I describe the analyses for PARP14. I developed novel assay 
methods for detecting PARP14 activity. Moreover, I identified potent, selective, and 
cell-permeable compounds by HTS. The inhibition mechanism of the hit compounds 
was analyzed by solving the X-ray crystal structure of PARP14 in complex with certain 
hit compounds. In the second chapter, I describe the analyses for DDX41. I evaluated 
the ATPase activities of human DDX41 which is dependent on ATP and dsDNA. Then, 
novel selective inhibitors of DDX41 were identified through HTS.  
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The results of these analyses provide an ideal platform for the discovery of PARP14 
and DDX41 inhibitors, present new chemical tools to investigate the multiple functions 
of these enzymes, and open a new horizon for drug discovery research related to STAT6 
signaling. 
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Chapter 1 : Identification of PARP14 Inhibitors Using Novel Methods for Detecting 
Auto-ribosylation 
 
Abstract 
 Poly(ADP-ribose) polymerases (PARPs) use nicotinamide adenine dinucleotide 
(NAD
+
) as a co-substrate to transfer ADP-ribose when it releases nicotinamide as the 
metabolized product. Enzymes of the PARP family play key roles in detecting and 
repairing DNA, modifying chromatin, regulating transcription, controlling energy 
metabolism, and inducing cell death. PARP14, the original member of the PARP family, 
has been reported to be associated with the development of inflammatory diseases and 
various cancer types, making it a potential therapeutic target. In this study, I purified the 
macrodomain-containing PARP14 enzyme and established an assay for detecting the 
auto-ribosylation activity of PARP14 using RapidFire high-throughput mass 
spectrometry and immunoradiometric assay using [
3
H]NAD
+
. Subsequently, I 
performed high-throughput screening using the assays and identified small-molecule hit 
compounds, which showed NAD
+
-competitive and PARP14-selective inhibitory 
activities. Co-crystal structures of PARP14 with certain hit compounds revealed that the 
inhibitors bind to the NAD
+
-binding site. Finally, I confirmed that the hit compounds 
interacted with intracellular PARP14 by a cell-based protein stabilization assay. Thus, I 
successfully identified primary candidate compounds for further investigation. 
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Introduction 
Poly(ADP-ribose) polymerases (PARPs) are a family that share the PARP motief to 
catalyze the transfer of ADP-ribose to target proteins [35]. PARPs catalyze the 
formation of linear or branched poly(ADP-ribose) chains, which are dynamic structures 
recognized by reader domains and that are broken down by poly(ADP-ribose) 
glycohydrolases [36]. Seventeen genes in the human genome possess PARP domains 
and each PARPs are endowed a variety of other functional domains [37]. A subset of the 
PARP family catalyzes mono-ADP-ribosylation but not chain elongation [38], and 
functional analyses on such mono-ADP-ribosyltransferases have been performed [39, 
40]. Most of these combine an ADP-ribosyltransferase domain with 
ADP-ribose-binding macrodomains, WWE domains, CCCH-type zinc finger domains, 
and other protein-protein interaction modules. PARP14 has three macrodomains which 
is predicted as interacting with ADP-ribose and considered as a 
mono-ADP-ribosyltransferase [41]. 
Previous reports indicated that PARP14 enhances IL-4-induced gene expression by 
interacting with the cytokine induced signal transducer and activator of STAT6 in B and 
T cells [42, 43]. In the absence of IL-4, PARP14 was found to be bound to STAT6 
responsive promoters, and functioned as a transcriptional repressor by recruiting HDAC 
2, 3 and p100 co-factor. In the presence of IL-4 the catalytic activity of PARP14 
modified the HDACs and the repressive complex was displaced from the promoter to 
activate transcription. PARP14 is required for STAT6-dependent gene expression. These 
studies indicated that PARP14 has the ability to bind DNA but the exact sequence to 
which PARP14 binds is not known. PARP14 protein was predominantly expressed in 
lymphoid tissues (spleen, thymus, and lymph nodes) [43]. This lymphoid pattern of 
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expression suggested that PARP14 may function predominantly in the immune system. 
The expression profile of genes between wild type (WT) and PARP14 knockout 
(PARP14−/−) Th2 cells were analyzed to define the mechanism PARP14 participates in 
Th2 cell differentiation and impacts allergic airway disease [42]. The Th2 cytokine 
genes Il4, Il5 and Il13 were reduced in PARP14 −/− Th2 cells. Moreover, the RNA pol 
II binding profile of genes in Th2 differentiation was analyzed and Gata3 was reduced 
due to PARP-14 deficiency. These results suggest that PARP14 may regulate the 
expression of GATA3 by controlling the binding ability of STAT6 to the Gata3 
promoter [42]. Therefore, PARP14 is considered as a promising drug target for STAT6 
related disease. However, the methods for evaluating the activities of PARP14 inhibitors 
have focused on biophysical assays, such as thermal shift assay, small-molecule 
microarrays, isothermal titration calorimetry, and differential scanning fluorimetry 
[44-48]. However, only the enzyme-linked immunosorbent assay has been reported to 
be suitable for evaluating enzymatic activity, and this method is time consuming 
because of the requirement for washing steps. Therefore, I here report a novel assay 
method using RapidFire high throughput mass spectrometry (HTMS) to evaluate 
PARP14 activity. HTMS is an attractive method for label-free screening of enzyme 
targets by directly quantifying native, unmodified substrates and products based on their 
mass-to-charge ratio; it has also recently been successfully used for screening some 
enzymes[49, 50]. 
In my study described in Chapter 1, novel assay methods for evaluating the 
autoribosylation activity of PARP14 by HTMS and immunoradiometric assay were 
established. Through these assays, I conducted a screening analysis from a library of 
more than approximately 500,000 compounds and identified hit compounds. Moreover, 
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I showed that co-crystallization of PARP14 and some hit compounds occurred, 
indicating that the inhibitors interacted with the nicotinamide adenine dinucleotide 
(NAD
+
) -binding site. Finally, I confirmed that the identified hit compounds could 
interact with intracellular PARP14 by a cell-based protein stabilization assay. The 
primary candidate compounds were successfully identified, so I conclude that these 
results represent a significant advance in PARP14-related research. 
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Materials & Methods 
Phylogenetic analysis of PARP14 
By Basic Local Alignment Search Tool Protein (blastp) searches, we collected 38 
PARP14 sequences including a human PARP14 from non-redundant protein sequences 
(nr) database of National Center for Biotechnology Information (NCBI, 
http://www.ncbi.nlm.nih.gov/) by using the human PARP14 sequence (NP_060024.2) as 
a query. Hit sequences that possess three macro domains characteristic PARP14 with 
E-value less than 1 x 10
-10
 were selected. Sequences were aligned using Muscle 
program [51] in SeaView package version 4.6.1 [52]. We selected 1,251 positions of 
unambiguously aligned by manual and used for phylogenetic analyses. The data matrix 
for phylogeny were subjected to the RAxML program version 8.2 [53]. GTR + 4 
model for amino acid substitution process was applied to infer the maximum likelihood 
(ML) tree. In the bootstrap analysis, heuristic tree search was performed with a rapid 
bootstrap algorithm option (-f) for 100 bootstrap replicates. Bootstrap proportion (BP) 
values were indicated on the corresponding internal branches of the ML tree drawn by 
the use of FigTree program Version 1.4.2 (http://tree.bio.ed.ac.uk/software/figtree/). 
 
Protein Expression and Purification 
To express human PARP14 (residues 791–1801) in insect cells, an entry plasmid, 
pENTRGST(V)/hPARP14 (791–1801), was constructed using a human heart cDNA 
library (Takara Bio, Kusatsu, Japan) as a template. A DNA fragment encoding human 
PARP14 (791–1801) was amplified by polymerase chain reaction (PCR) using 
PrimeSTAR® GXL DNA Polymerase (Takara Bio), and the PCR product was ligated to 
the EcoR I/Not I site of  the pENTR-D-TOPO vector (Thermo Fisher Scientific, 
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Waltham, MA), preceded by insertion of a sequence for the N-terminal GST-tag. 
Baculovirus was prepared using the BaculoDirect™ Baculovirus Expression System 
(Thermo Fisher Scientific) using pENTRGST(V)/hPARP14 (791–1801). Sf9 cells were 
infected with baculovirus and cultured for 72 h. Recombinant proteins were purified by 
affinity chromatography and gel filtration chromatography. All purification steps were 
performed at 4°C. Harvested Sf9 cells were suspended in lysis buffer [50 mM HEPES 
(pH 8.0), 150 mM NaCl, 3 mM DTT, 20% glycerol, 0.04% Tween 20, 2 mM KCl, and 5 
U/mL Benzonase], sonicated for 3 min, and then centrifuged at 13,000 × g for 40 min at 
4°C. The supernatant was incubated with 45 mL of glutathione-Sepharose™4B resin 
(GE Healthcare, Little Chalfont, UK) equilibrated with buffer A [50 mM HEPES (pH 
8.0), 150 mM NaCl, 3 mM DTT, 20% glycerol, 0.04% Tween 20, and 2 mM KCl] for 
60 min. The resin was washed with 270 mL of buffer A and then GST-tagged PARP14 
(residues 791–1801) was eluted with 20 mM reduced glutathione in the same buffer. 
The eluate containing GST-tagged PARP14 (791–1801) was concentrated using an 
Amicon Ultra-15 (Millipore, Watford, UK). GST-tagged PARP14 (791–1801) was 
further purified by gel filtration chromatography with a HiLoad 26/600 Superdex 200 
pg column (GE Healthcare) equilibrated with buffer A. 
 
RapidFire Mass Spectrometry 
The PARP14 enzyme reaction was conducted with 100 nM GST-tagged PARP14 and 
0.5 mM NAD
+
 diluted with assay buffer [50 mM HEPES (pH 8.0), 10 mM MgCl2, 1 
mM DTT, 0.01% Tween20, and 0.01% BSA] in a 384-well polypropylene plate 
(Corning, Corning, NY) at a final volume of 2 μL. The reaction was performed for 120 
min and terminated by adding 60 μL of 4% formic acid containing 6.3 μM 
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nicotinamide-d4 (C/D/N Isotopes, Quebec, Canada).  
HTMS was performed using a RapidFire300 system (Agilent, Santa Clara, CA) 
coupled to an Agilent6490 triple quadrupole mass spectrometer (Agilent). The samples 
were loaded onto a Graphitic Carbon cartridge (Agilent) using 0.1% trifluoroacetic acid 
in deionized water at a flow rate of 1.5 mL/min and eluted to the mass spectrometer 
using 0.05% trifluoroacetic acid in acetonitrile/acetone/deionized water (70/20/10, 
v/v/v) at a flow rate of 1.0 mL/min. The sipper was washed to minimize carry over with 
deionized water followed by acetonitrile. Aspiration time, load/wash time, elution time, 
and re-equilibration time were adjusted to 350, 3000, 5000, and 1000 ms, respectively, 
for a cycle time of approximately 10 s. The mass spectrometer equipped with an 
electro-spray ion source was operated in positive multiple reaction monitoring (MRM) 
mode. The MRM transitions (Q1/Q3) for nicotinamide as a reaction product and 
nicotinamide-d4 as an internal standard were set as 123.0/80.0 and 127.0/84.1, 
respectively. For the NAD
+
 competition assay, the samples were measured by an 
ultra-high-performance liquid chromatography Nexera MP system (Shimadzu, Kyoto, 
Japan) coupled to Agilent6490. 
The inhibitory activity was calculated using the peak area ratio, which is the reaction 
product divided by its internal standard. I defined the peak area ratio of the reaction 
without enzyme as 100% inhibitory activity and that of the complete reaction mixture as 
0% inhibitory activity. Curve fittings and calculations of IC50 values were performed 
with GraphPad Prism V.5 (GraphPad Software, San Diego, CA). 
 
Immunoradiometric Assay 
 Assay methods for detecting the auto-ribosylation activity of PARP14 and PARP1 
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were established using [
3
H]NAD
+
. The enzyme reaction was performed on a plate 
coated with anti-GST antibody (GE Healthcare). The PARP14 enzyme reaction was 
conducted with 30 nM GST-tagged PARP14 and 80 nM [
3
H]NAD
+
 diluted with assay 
buffer [50 mM HEPES (pH 8.0), 1 mM MgCl2, 1 mM DTT, 0.01% BSA (Sigma, 
Darmstadt, Germany)] for 210 min at room temperature. The reaction was terminated 
by washing with PBST buffer and MicroScint-PS (PerkinElmer, Waltham, MA) was 
added to the plate. In the case of the PARP1 selectivity assay, the enzyme reaction was 
conducted with 7.1 nM GST-tagged PARP1 (BPS Bioscience, San Diego, CA), 30 nM 
[
3
H]NAD
+, and 2 μg/mL activated DNA (Trevigen, Gaithersburg, MD) diluted with 
assay buffer for 210 min at room temperature. Radioactivity formed by autoribosylated 
PARP1 and PARP14 was read using a TopCount (PerkinElmer). The inhibitory activity 
was calculated in the same way as for HTMS. 
 
Crystallization and Structure Determination of Human PARP14  
A clone was made as per a previously published structure reported by the Structural 
Genomics Consortiu [44]. The region of PARP14 covering residues 1611–1801 was 
cloned into Escherichia coli (E. coli) vector containing a kanamycin resistance marker 
and a tobacco etch virus (TEV) protease cleavage site. E. coli Rosetta DE3 strain was 
scaled up for large-scale expression and purification. Cells were lysed by sonication 
followed by centrifugation at 17,968 x g for 1 h. The supernatant was loaded on an 
affinity NiNTA column (Qiagen, Hilden, Germany) and purified using an increasing 
linear gradient of nickel sulfate (20–200 mM). The eluate was checked for purity and 
treated with TEV protease followed by size exclusion chromatography on a HiLoad 
26/600 Superdex 200 pg (GE Healthcare). After confirmation of the pure fractions, 
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protein was concentrated to 38.2 mg/ml in buffer [25 mM Tris (pH 7.9), 200 mM NaCl, 
and 0.5 mM TCEP] and used for structural studies. Initial screening in a PEG Ion screen 
(Hampton Research, Aliso Viejo, CA) yielded several hits both with apo protein and in 
the presence of 1 mM concentration of compounds. However, the best diffracting 
crystals appeared when optimized under the following conditions [20% PEG3350 and 
0.2 M sodium-malonate (pH 7.2–7.8)]. Crystals were harvested after cryoprotection 
with either 15% ethylene glycol or 15% glycerol for 15 min. 
 Data were collected at Beamline 5.0.3 of the Advanced Light Source at Berkeley (CA, 
USA). The structure was solved by molecular replacement using Molrep [54] of the 
CCP4 package [55]. PDBId 3GOY was used as the starting model. This was followed 
by iterative rounds of manual model building in Coot [56] and restrained refinement 
using Refmac5 [57]. The ligand atoms and water molecules were fit manually after 
interpreting the difference map and accounting for the protein atoms.  
 
Intracellular PARP14 Stability Assay 
 The A549 cell line stably expressing NanoLuc-fuzed PARP14 (PARP14-NanoLuc, 
residues 1611–1801) was established and cultured in DMEM medium (Wako Pure 
Chemical Industries, Ltd., Osaka, Japan) supplemented with 10% fetal bovine serum 
(Corning) and 0.5 mg/mL G-418 (Wako).  
After seeding 5,000 cells per 20 μL of medium into a white opaque 384-well plate 
(Corning) overnight, 5 μL of test compounds were added to the cell plate, which was 
then incubated for 6 h at 37°C in 5% CO2 and 95% humidity. In the final step, 25 μL of 
Nano-Glo Luciferase substrate (Promega, Fitchburg, WI) was added to the assay plate 
and luminescence was read using an EnVision plate reader (PerkinElmer). The 
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inhibitory activity was calculated using the luminescence data and curve fittings and 
calculations of EC50 values were performed with GraphPad Prism V.5 (GraphPad 
Software). 
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Results 
Phylogenetic Analysis of PARP14 
 To evaluate what kind of organisms possess PARP14 containing three macro domains, 
molecular evolutionary analysis was performed. The blastp search using human 
PARP14 as a query revealed that PARP14 homologs with three macro domains are 
present only in restricted metazoan lineages, Porifera (sponges), Cnidaria, and Chordata. 
Although I could not find the PARP14 homologs in other metazoan phyla including 
Arthropoda, the presence of PARP14 in the earliest branching metazoan phylum, 
Porifera, suggests the presence of PARP14 in the common ancestor of metazoan 
lineages. Outside Metazoa I could neither find the PARP14 homologs in 
choanoflagellates nor in fungi or plants, also suggesting the emergence of PARP14 in 
the ancestral metazoan lineage. In the ML tree of PARP14 (Figure 6), several lineage 
specific gene duplications were observed, while in mammals only a single gene was 
present. On the branch leading to each of the duplicated genes of Ciona intestinalis, the 
evolutionary rate might have been accelerated. Although the putative homologs of 
STAT6 protein was conserved not only in diverse metazoans but also in amoeba 
(Dictyostelium) [58], the function of the STAT6 homologs except for model animals 
have not been clarified in detail. However, in the origin of animals the STAT6 signal 
might have needed to be more complex in order to evolve multicellularity of animals. 
Considering such situation, PARP14 might have been established in the common 
ancestor of metazoans as an additional enzyme for regulating the complex STAT6 signal. 
Since then it has been conserved during the evolution leading to vertebrates, but has 
been lost in several other metazoan lineages. 
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Assay Development for Evaluating PARP14 Auto-ribosylation Activity  
To evaluate the auto-ribosylation activities of PARP14, HTMS and 
immunoradiometric assays were established. The HTMS assay was initially developed 
for the primary screen. PARP14 was titrated and the reaction was monitored for 120 min 
(Fig. 7A). The production of nicotinamide by PARP14 increased over time in a linear 
manner and the Km value of NAD
+
 was determined to be 1.2 mM (Fig. 7B). The 
condition for the screen was set to 500 μM NAD+, 0.1 μM PARP14, and a reaction time 
of 120 min. To validate the assay, PJ-34 (Wako), a known PARP family inhibitor, was 
titrated under the optimized assay conditions and determined to have an IC50 value of 
9.0 μM (Fig. 7C). High reproducibility of the compound activities was confirmed by 
HTMS assay (Fig. 7D). Moreover, an immunoradiometric assay was also developed 
using [
3
H]NAD
+
 to detect the PARP14 auto-ribosylation activity. Titration of [
3
H]NAD
+
 
and PARP14 was monitored for 240 min (Fig. 8A, B), resulting in the assay conditions 
of 30 nM PARP14, 80 nM [
3
H]NAD
+
, and a reaction time of 210 min to keep a stable 
signal-to-noise ratio of approximately 3.5. The IC50 of PJ-34 was 2.5 μM, which is 
comparable to the activity detected by HTMS (Fig. 8C). 
 
Identification and Characterization of Novel Inhibitors  
A diverse library of more than approximately 500,000 small-molecule compounds in 
Takeda Pharmaceutical Company was screened at 3 μM, as shown in the work flow (Fig. 
9A, B). The initial hit compounds were eliminated and possessed almost the same 
activities in the HTMS and immunoradiometric assays. To elucidate the mechanism of 
inhibition, a substrate competition assay was performed. The rates of PARP14 inhibition 
by the compounds were examined in the two conditions described in the Materials & 
36 
 
Methods. The representative hit compounds listed in Table 3 showed lower IC50 by a 
20-fold increase in NAD
+
 concentration (Table 3). The results indicated that these hit 
compounds possessed competitive inhibitory activity against NAD
+
. These results were 
supported by the co-crystallization of PARP14 and hit compound, as described below. 
Moreover, a selectivity assay against PARP1 was conducted. Compound 1 
(6-{3-[4-(diphenylmethoxy)piperidin-1-yl]propoxy}[1,2,4]triazolo[4,3-b]pyridazine) 
showed no activity against PARP1 at a concentration of 30 μM, while compound 2 
(2-[(pyridin-4-ylmethyl)amino]-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H
)-one) has an IC50 value of 26 μM (Table 3). 
 
X-ray Crystal Structure of PARP14 in Complex with Hit Compounds  
To elucidate the mode of binding of the inhibitor with PARP14, I obtained X-ray 
crystal structures of PARP14 in complex with the hit compounds. I selected compound 
3 
(N-{4-[4-(diphenylmethoxy)piperidin-1-yl]butyl}[1,2,4]triazolo[4,3-b]pyridazin-6-amin
e) and compound 4 
(2-{[(1-methylpiperidin-4-yl)methyl]amino}-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]py
rimidin-4(3H)-one), which belong to the same chemotypes as compound 1 and 
compound 2, respectively. The IC50 values of compound 3 and compound 4 are 610 nM 
and 76 nM in the immunoradiometric assay of PARP14. Data collection and refinement 
statistics of the structures are shown in Table 4. Compound 3 binds to the catalytic site, 
making several key interactions, mainly with the terminal bicyclic core (Fig. 10A). Two 
of the triazole nitrogens form hydrogen bonds, one with the Ser1722 side chain 
hydroxyl and the other with the Gly1683 backbone NH. The bicyclic plane of the 
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inhibitor stacks parallel to the side chain of Tyr1727. The rest of the aliphatic tail and 
the terminal phenyl rings are exposed to the solvent. Unsurprisingly, the density in the 
difference map is lower for this region of the inhibitor. The loop of residues 1699–1710 
is disordered in this structure. The two terminal phenyl rings, however, are involved in 
crystal contact-mediated interactions with an adjacent molecule, where they face 
residues Asn1720 and Tyr1721.  
In the case of compound 4, the planar tricyclic ring binds to the active site sandwiched 
between the aromatic rings of Tyr1727 and Try1714 (Fig. 10B). The sulfur atom faces 
the solvent side, while the carbonyl and the pyrimidine nitrogen atom form hydrogen 
bonds with the backbone NH and carbonyl of Gly1683, respectively. Additionally, the 
inhibitor carbonyl forms a hydrogen bond with the hydroxyl of Ser1722. The terminal 
methyl piperidine faces the solvent orienting toward the side chains of Asp1685 and 
Ser1688. Atom coordinates and structure factors for complexes will be deposited in the 
Protein Data Bank. 
The obtained crystal structures were compared with the crystal structure of PARP1 
(PDB ID: 4L6S). An overlay of these structures is shown in Fig. 10C for compound 3 
and Fig. 10D for compound 4. It was revealed that the two terminal phenyl rings in 
compound 3 and the terminal methyl piperidine ring of compound 4 sterically clashed 
with part of the PARP1 protein. These observations are well consistent with the assay 
results that hit compounds exhibited good selectivity against PARP1.  
 
Detecting Interaction Activity of Intracellular PARP14 
 To evaluate the cellular activities of the representative hit compounds including 
compounds 1–4, a novel detection system for quantifying the interaction of transfected 
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PARP14-NanoLuc with hit compounds inside the cell was established. The 
accumulation of PARP14-NanoLuc for 6 h after treatment with the compound was 
detected. A correlation plot of the pIC50 values of enzyme immunoradiometric assay 
compared with the cell-based protein stabilization assay shows a high positive 
correlation (Fig. 11, r=0.82). The hit compounds are cell-permeable and interact with 
the intracellular PARP14. 
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Discussion 
In this section, I established assay methods for detecting PARP14 activity. Moreover, I 
identified potent, selective, and cell-permeable compounds through high-throughput 
screening (HTS). A strategy for creating potential lead compounds can be developed by 
solving the X-ray crystal structure of PARP14 when in complex with certain hit 
compounds. 
A variety of assays have been used to identify potential PARP14 inhibitors [45] [46] 
[47] [48], but the methods of evaluating PARP14 enzymatic activities have been less 
well studied. I established an HTS assay for PARP14 with HTMS, which is beneficial as 
it involves a label-free method that can quantify native, unmodified substrates and 
products based on their mass-to-charge ratio. Macrodomain-containing purified 
PARP14 was used because it possesses the conserved ADP-ribose binding motif [39] 
[40] [41], but the differences in activity between non-ribosylated and ribosylated 
PARP14 were not determined in the auto-ribosylation assay because the enzyme itself 
can also serve as an acceptor. In the future, it might be necessary to analyze the 
molecular function of PARP14 by identifying endogenous substrates other than the 
enzyme itself, before studying the reaction mechanism. 
Some compounds were identified through HTS, I also developed a PARP1 selectivity 
assay to verify the specificity of enzymatic inhibition, and a cell-based protein 
stabilization assay to estimate cellular activity. The hit compounds possessed potent 
inhibitory activities, as shown in Table 3, with both competitive activities against NAD
+ 
and target interaction activities in the cells. These HTS results indicate that PARP14 is a 
highly druggable target and hit compounds directly target PARP14. By 
co-crystallization analysis and NAD
+
 competition assay, I also demonstrated that there 
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was a prominent binding site for small-molecule inhibitors that overlapped with the 
NAD
+
 binding site. Based on the crystal structural information, it would be possible to 
guide these hit compounds into good lead compounds as PARP14 inhibitors. Regarding 
compound 3, the aliphatic tail and the terminal phenyl rings do not show specific 
interactions with PARP14 and it is suggested that a shorter tail or a smaller terminal 
group would be sufficient for steric repulsion with PARP1. Taking these findings 
together, modification of the aliphatic tail and terminal phenyl rings to a smaller 
substructure would maintain both inhibitory activity and good selectivity against PARP1. 
In the case of compound 4, it was expected that the introduction of substituents to the 
terminal piperidine ring that were intended to interact with Asp1685 and Ser1688 would 
enhance inhibitory activity without losing good selectivity against PARP1. 
In another part of the research, I established a method of cell-based monitoring of the 
interaction between small-molecule inhibitors and intracellular targets using a NanoLuc 
luciferase detection system (Promega) because the direct marker of PARP14 was 
unknown. Ligand-induced protein stabilization is a proven phenomenon [59-61] , and 
recent reports have described assay systems using enzyme fragment complementation, 
time-resolved fluorescence resonance energy transfer, and cellular thermal shift [62-64]. 
It was confirmed that the compounds with functional cellular or tissue activity could 
stabilize the intracellular target molecule. Therefore, the cell-based protein stabilization 
assay of PARP14 can be considered an efficient way to validate target engagement, with 
NanoLuc luciferase detection being a well-established and robust method that is 
frequently used in drug screening for high-sensitivity detection [65]. Because NanoLuc 
luciferase has a low molecular weight (19 kDa), it is well suited for use as a protein 
fusion tag, allowing luminescence to be associated with the physiological dynamics of 
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specific intracellular proteins. The protein stabilization induced by small-molecule 
compounds was measured by quantification of the intracellular transfected 
PARP14-NanoLuc fusion protein. Some hit compounds identified through HTS showed 
a correlation for the IC50 values obtained by enzyme assay and the PARP14 cell-based 
stabilization assays (Fig. 11). 
Finally, it has been reported that PARP14 is expressed in lymphoid organs and 
lymphocyte cells, and that it has a significant role in the development of allergic 
inflammation [24, 25, 66-69]. PARP14 has also been shown to promote the Warburg 
effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 
phosphorylation [70]. Such reports raise the possibility that targeting PARP14 may 
result in the development of effective therapies for inflammatory diseases and various 
cancers. In the future, it will be possible to conduct functional cell analyses using the 
putative inhibitors that I obtained, which may help to elucidate the contribution of 
PARP14 to these diseases. The compounds I identified have the potential to make a 
significant contribution to research concerning PARP14. In conclusion, my study 
provides an ideal platform for the discovery of PARP14 inhibitors, and presents new 
chemical tools for use in investigating the multiple functions of PARP14. 
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Figures and Tables 
 
 
 
Figure 6. Phylogenetic tree of PARP14. The ML tree inferred by RAxML program using 
the GTR +  4 model was shown. Different colors were used to differentiate species in 
Cordata. Branch lengths are proportional to the number of amino acid substitutions/site. 
Numbers on the internal branches denote bootstrap proportion values.       
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Figure 7. PARP14 high-throughput mass spectrometry (HTMS) assay development.  
(A) Time course of PARP14 in the presence of 100 nM or 30 nM PARP14. 
Nicotinamide production by PARP14 increased in a linear manner for 120 min. (B) 
Determination of the kinetic constants for NAD
+
. The study analysis was performed 
under the assay conditions of 0.1 μM PARP14 and an increasing concentration of NAD+. 
The Km value (95% confidence interval) for NAD
+
 was 1.2 mM (0.79–1.5 mM). (C) 
Dose-dependent inhibition of PARP14 by PJ-34. The IC50 (95% confidence interval) 
value was 9.0 μM (7.5–10 μM). (D) Correlation between replicates of percentage 
inhibition of the test compounds. x-axis is replicate 1 and y-axis is replicate 2 (r=0.34). 
Data shown are mean ± SD of n = 2 technical replicates and are representative of two 
independent experiments. 
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Figure 8. PARP14 immunoradiometric assay development. 
 (A) Time course of PARP14 auto-ribosylation activity at 100 nM, 30 nM, or 10 nM 
[
3
H] NAD and 30 nM PARP14. (B) Auto-ribosylation activity with 100 nM, 30 nM, or 1 
nM PARP14. (C) Dose-dependent inhibition of PARP14 by PJ-34. IC50 (95% 
confidence interval) value was 2.5 μM (1.5–4.3 μM). Data shown are mean ± SD of n = 
2 technical replicates and are representative of two independent experiments. 
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Figure 9. Results of primary screening and profiling assays. 
(A) The HTS flow consists of primary screening, profiling assay, hit validation, and 
characterization. (B) A diverse library of small compounds at Takeda Pharmaceutical 
Company was screened at 3 μM against PARP14, as shown by the histogram. 
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Figure 10 Crystal structures of PARP14 in complex with hit compounds. 
 (A, B) Interactions of ligands with PARP14 regarding compound 3 (A) and compound 
4 (B). Hydrogen bonds between ligands and PARP14 are depicted as dotted lines. (C,D) 
Overlay of PARP1 and PARP14 in complex with compound 3 (C) and compound 4 (D), 
respectively. PARP1 protein is depicted as a yellow surface. 
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Figure 11. A correlation plot of the pIC50 values determined by enzyme 
immunoradiometric assay and cell-based protein stabilization assay (r=0.82). The black 
circles represent compounds 1–4. 
IC50 values of compounds 1–4 are 590, 330, 710, and 350 nM, respectively.  
4
5
6
7
8
9
4 5 6 7 8 9
p
IC
5
0
 o
f 
im
m
u
n
o
ra
d
io
m
e
tr
ic
 e
n
z
y
m
e
 a
s
s
a
y
pEC50 of cell-based protein stabilization assay 
Compound 1
Compound 4
Compound 2
Compound 3
48 
 
Table 3. IC50 values and 95% confidence intervals of the hit compounds in various 
assays 
  
Compound ID structure 
Immunoradiometric assay   RapidFire HTMS   
  
PARP14 
 IC50 (μM) 
PARP1 
 IC50 (μM) 
  
PARP14 
IC50 (μM) 
PARP14 
IC50 (μM) 
  
    
500 μM 
NAD
+
 
10 mM 
NAD
+
 
  
  Compound 1  
0.58 
(0.38–0.87) 
>30   
2.8 
(1.9–4.1) 
13 
(10–17) 
  
  Compound 2  
0.31 
(0.27–0.36) 
26 
(5.5–91) 
  
1.3 
(1.1–1.6) 
6.2 
(4.1–9.3) 
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Table 4. X-ray data 
Data Collection    Compound 3     Compound 4     
Beamline 
 
SSRL 7-1 
  
SSRL 14-1 
  
Space group  
 
P6222  
  
C2221  
  
Unit cell parameters  
 
a = 83.3 Å  α = 90° 
 
a = 83.0 Å α = 90° 
 
  
b = 83.3Å β = 90° 
 
b = 144.9Å  β = 90° 
 
  
c = 129.9 Å  γ = 120° 
 
c = 83.4Å  γ = 90° 
 
Wavelength (Å)  
 
1.1271 
  
1.2398 
  
Resolution range (Å)  
 
50.0–2.35  
  
30.0–2.6  
  
Number of observations  
 
738,119 
  
556,336 
  
Number of unique reflections  
 
14,218 
  
16,050 
  
Completeness (%)  
 
95.5 (86.2)  
  
99.8 (97.8)  
  
Redundancy  
 
5.7 
  
3.7 
  
Mean I/σ (I)  
 
24.1 (1.9)  
  
9.8 (1.2)  
  
Rsyma on I  
 
0.079 
  
0.171 
  
Highest-resolution shell (Å)  
 
2.41–2.35  
  
2.65–2.58  
  
        
Refinement 
       
R-work  
 
22 
  
20.3 
  
R-free  
 
29.6 
  
26.4 
  
Average B factor 
 
43.1 
  
23.6 
  
Rmsd bond length (Å)  
 
0.005 
  
0.007 
  
Rmsd bond angle (°)  
 
0.889 
  
1.05 
  
Ramachandran statistics  
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 Preferred region (%)  
 
97.6 
  
95.2 
  
 Allowed region (%)  
 
1.8 
  
4.18 
  
 Outlier (%)   0.6     0.6     
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Chapter 2 : High-throughput Screening to Identify Inhibitors of DEAD Box Helicase 
DDX41 
 
Abstract 
The human DEAD (Asp–Glu–Ala–Asp) box protein DDX41, a member of the DEXDc 
helicase family, has nucleic acid-dependent ATPase and RNA and DNA translocase and 
unwinding activities. DDX41 is affected by somatic mutations in sporadic cases of 
myeloid neoplasms as well as in a biallelic fashion in 50% of patients with germline 
DDX41 mutations. The R525H mutation in DDX41 is thought to play important roles in 
the development of hereditary myelodysplastic syndrome and acute myelocytic 
leukemia.  
In this study, human DDX41 and its R525H mutant (R525H) were expressed in 
Escherichia coli and purified. The ATPase activities of the recombinant DDX41 and 
R525H proteins were dependent on both ATP and double-stranded DNA (dsDNA), such 
as poly(dG–dC) and poly(dA–dT). High-throughput screening was performed with a 
dsDNA-dependent ATPase assay using the human R525H proteins. After hit 
confirmation and counter screening, several small-molecule inhibitors were successfully 
identified. These compounds show DDX41-selective inhibitory activities. 
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Introduction 
 A comprehensive genetic analysis identified a somatic mutation in the DDX41 gene 
encoding a DEAD (Asp–Glu–Ala–Asp) box-type adenosine triphosphate (ATP)–
dependent RNA helicase. The somatic mutations of DDX41 are dominated by 
c.G1574A (p.R525H). Germline mutations in DDX41 were recently isolated in a subset 
of familial acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) pedigrees. 
Spliceosomal proteins constitute the top functional group associated with DDX41 and 
R525H alter the native DDX41 interaction especially for the U2 and U5 spliceosomes. 
It was considered that DDX41 defects lead to loss of tumor suppressor function due to 
altered pre-mRNA splicing and RNA processing [71]. The R525H mutation not only 
causes a defect in pre-rRNA processing but also inhibits cell cycle progression [72]. The 
R525H mutant (R525H) might also play an important role in tumorigenesis and 
therefore provides a drug target for cancer therapy [73-76]. R525H residue in DDX41 is 
located at the C-terminus of the RecA-like helicase core domain where ATP might 
interact. Though it is expected that R525H might show the different helicase activity 
compared to DDX41, the enzymatic activities are not evaluated so far. 
DDX41 is a member of the DEXDc family of ATP dependent helicases. [77, 78] 
DEAD-box proteins, which contain the conserved sequence Asp–Glu–Ala–Asp, play 
essential roles in DNA and RNA metabolism, including in their replication, repair, 
recombination, transcription, translation, ribosome biogenesis, and splicing, which 
regulate growth and development [79, 80].  The analysis of phylogenetic tree revealed 
DDX41 is conserved in eukaryotes especially in animals [81]. Although DDX41 might 
be an important molecule in the progress of the STAT6 signal's evolution, the 
mechanism of how it functions is still unknown. DDX41 has also been shown to sense 
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microbial DNA, triggering the early induction of Chemokines and type I IFNs in mouse 
splenic myeloid dendritic cells [29, 33]. When it is stimulated with poly(dA–dT) or 
poly(dG–dC) in some cell-based assays, DDX41 combines with these polynucleotides 
physically and interacts with the downstream adaptor molecule STING and TBK1, 
triggering the activation of interferon regulatory factor 3 (IRF3) and nuclear 
factor-kappa B (NF-κB), which are important transcription factors in the regulation of 
type I IFN expression [34, 82]. A recent study also determined the crystal structures of 
the DDX41 DEAD domain in the apo form [73]. However, very little is known about 
the enzyme dynamics of DDX41 [72, 83]. In the present study, I cloned the full-length 
cDNA of human DDX41, R525H and ATPase defective E345Q mutant (E345Q), 
characterized the proteins’ functions with an ATPase activity assay and used HTS to 
identify R525H inhibitors. E345Q which was expected to be defective in ATP 
hydrolysis activity based on an analysis of eIF4A3 [84], to confirm the difference in the 
ATPase activities of DDX41 and E345Q and rule out the possibility that the 
dsDNA-dependent ATPase activity observed with purified DDX41 was actually due to a 
contaminant. The purified human DDX41 and R525H enzymes showed ATPase activity 
against poly(dG–dC) or poly(dA–dT). On the other hand, E345Q showed no ATPase 
activity. Various compounds were found to inhibit R525H and DDX41. These results 
constitute significant advances in the biochemical research into DDX41 
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Materials and Methods 
Cloning 
The genes encoding DDX41, R525H, and E345Q (ATPase defective mutant) were 
amplified with polymerase chain reaction (PCR) using PrimeSTAR® Max DNA 
Polymerase (Takara Bio, Kusatsu, Japan), with which BamHI and NotI restriction sites 
were inserted upstream and downstream from DDX41, respectively. The primer 
sequences for DDX41 were F1, 
5′-GTACTTTCAGGGATCCATGGAGGAGTCGGAACCCGA-3′, and R1, 
5′-TGCTCGAGTGCGGCCGCTCAGAAGTCCATGGAGCTGTGGG-3′. R525H and 
E345Q were constructed with overlap extension PCR. The first round of PCR to 
amplify R525H was performed with primers F1 and R2 
(5′-TGTGTTTCCCGAGTGCCCGGTGCGGCCAAT-3′), and the open reading frame 
(Thermo Fisher Scientific, Waltham, MA) of the DDX41 gene was used as the template 
DNA. The second round of PCR was performed with primers F2 
(5′-ATTGGCCGCACCGGGCACTCGGGAAACACA-3′) and R1, and DDX41 was 
used as a template. In the third round of PCR, the products of the first- and 
second-round PCRs were used as the templates and amplified with the F1 and R1 
primers. To construct E345Q, the first round of PCR was performed with primers F1 
and R3 (5′ GATCATGCGGTCAGCCTGGTCCAGGGCCAGGTAGCGACA-3′), and 
DDX41 was used as the template. The second round of PCR was performed with 
primers F3 (5′-CCCTGGACCAGGCTGACCGCATGATCGACATG-3′) and R1, and 
DDX41 was used as the template. The third round of PCR was performed in the same 
way as that for R525H. The amplified gene was inserted into the pET21HH(V) vector 
using the In-Fusion HD Cloning Kit (Takara Bio) and introduced into E. coli JM109 to 
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isolate the plasmid. dnaK was amplified with PrimeSTAR GXL DNA Polymerase 
(Takara Bio) and restricted with the NdeI and NheI enzymes. The genomic DNA of E. 
coli BL21(DE3) was used as the template. The first round of PCR was performed with 
primers F4 (5′-AAGGAGATATACATATGGGTAAAATAATTGGTATCG-3′) and R4 
(5′-TCCCTGAAAGTACAGGTTCTCTTTTTTGTCTTTGACTTCTTCAAATTC-3′). 
The second round of PCR was performed with primers F5 
(5′-AAGGAGATATACATATGGGTAAAATAATTGGTATCG-3′) and R5 
(5′-CGTTCAGTCCGCTAGCTCCCTGAAAGTACAGGTTCTC-3′), and the PCR 
product amplified with the F4 and R4 primers was used as the template. After its 
digestion with restriction enzymes, the amplified gene was inserted into the 
pET21HH/hTARS-Avi-His vector using the In-Fusion HD Cloning Kit (Takara Bio) and 
introduced into E. coli JM109 for plasmid isolation. The isolated recombinant plasmids 
carrying DDX41, R525H, E345Q, and dnaK were introduced into E. coli BL21(DE3) 
(Nippongene, Toyama, Japan). 
 
Protein Expression and Purification 
E. coli BL21(DE3) clones were grown at 37 °C in Luria–Bertani broth to an optical 
density of 0.4 at 600 nm (OD600). Isopropyl -D -thiogalactoside was added at a final 
concentration of 1 mM and growth was continued for 5 h at 37 °C. The recombinant 
proteins were purified in two chromatographic steps. The cells were lysed with lysis 
buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 5 U/mL SEM nuclease, 20 mM 
imidazole, 10% [v/v] glycerol, and 1 mM dithiothreitol [DTT]). The lysate was 
sonicated three times for 15 s each and the suspension was centrifuged at 34,000 x g for 
30 min at 4 °C. The supernatant was applied to an affinity NiNTA column and 
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equilibrated with AF buffer A (50 mM Tris–HCl [pH 8.0], 300 mM NaCl, 10% [v/v] 
glycerol, and 1 mM DTT). The proteins bound to the column were eluted with a linear 
gradient of 0.005–0.5 M imidazole in AF buffer A. The positive fractions were collected 
and dialyzed against AF buffer B (AF buffer A containing 250 mM imidazole) at 4 °C. 
The dialyzed fractions were applied to a HiLoad 26/600 Superdex 200 pg (GE 
Healthcare UK Ltd., Little Chalfont, UK) previously equilibrated with GF buffer (50 
mM Tris-HCl [pH 8.0], 150 mM NaCl, 10% [v/v] glycerol, and 1 mM DTT). The 
fractions were pooled and eluted in GF buffer. 
The presence of the recombinant protein in the collected fractions was checked by 
staining with Coomassie Brilliant Blue (Thermo Fisher Scientific) and immunoblotting 
with a DDX41-specific antibody (Abnova, Taipei, Taiwan) , a His-tag-specific antibody 
(Wako Pure Chemical Industries, Ltd., Osaka, Japan) or a DnaK-specific antibody 
(in-house antibody). 
 
Mass Spectrometric Analysis  
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of the 
purified enzymes was performed with SYPRO Ruby Protein Gel Stain (Thermo Fisher 
Scientific). The protein bands were excised and digested with trypsin (Promega, 
Madison, WI) in a MultiScreen 96-well filter plate (Merck Millipore, Darmstadt, 
Germany). The tryptic digests were analyzed with nano-LC (Shimadzu, Kyoto, Japan) 
and an LTQ OrbitrapXL ETD Hybrid Ion Trap-Orbitrap Mass Spectrometer (Thermo 
Fisher Scientific), and identified using the Mascot database search system (Matrix 
Science, Boston, MA) and the SProt database. Data processing was performed by 
Proteome discoverer software ver. 1.4 (Thermo Fisher Scientific). The precursor mass 
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tolerance was set at 20 ppm, the fragment ion mass tolerance was 0.2 Da, and the false 
discovery rate was 0.01. 
 
DDX41 Enzymatic Activity Assay 
ATPase assays were performed with the ADP-Glo™ Kinase Assay (Promega), all of 
which were performed within the linear portion of the standard curve for the conversion 
of ATP to ADP. The kinetic parameters for ATP, poly(dG–dC), and poly(dA–dT) were 
determined by incubating various concentrations of each substrate with DDX41 or 
R525H for 30 min in 6 μL reaction volume in Greiner 784075 384-well microplates. 
The initial rate data were fitted to the Michaelis–Menten equation with GraphPad Prism 
v.5 (GraphPad Software Inc., San Diego, CA). The reactions for HTS were performed in 
a total volume of 1 μL in Greiner 782075 1536-well microplates and included 25 nM 
R525H enzyme, 70 μM ATP, and 0.2 μg/mL poly(dG–dC) (Sigma, Darmstadt, 
Germany) or poly(dA–dT) (Sigma) diluted with assay buffer (20 mM Tris-HCl [pH 7.5], 
100 mM KCl, 2.5 mM MgCl2, 1 mM DTT, 0.01% Tween 20, and 0.01% bovine serum 
albumin [Sigma]). After incubation for 120 min at room temperature, the reactions were 
terminated by the addition of 0.5 μL of ADP-Glo™ reagent (Promega). The samples 
were incubated for 40 min at room temperature before the addition of 1 μL of Kinase 
Detection Reagent™ (Promega). After 40 min at room temperature, the luminescence 
was read with an EnVision Multiplate Plate Reader (PerkinElmer, Waltham, MA). The 
assay quality of HTS was analyzed with the Z′ factor, which was calculated from the 
means and standard deviations of the 100% and 0% inhibitory activities. I considered 
the luminescent signals of the reaction without poly(dG–dC) to indicate 100% 
inhibitory activity and those of the complete reaction mixture to indicate 0% inhibitory 
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activity. Curve fitting and calculation of the 50% inhibitory concentrations (IC50) were 
performed with GraphPad Prism v.5 (GraphPad Software).  
The substrate competition assays using R525H enzyme were performed under the 
following four conditions: 70 μM or 700 μM ATP in the presence of 0.2 μg/mL 
poly(dG–dC), and 0.2 μg/mL or 2 μg/mL poly(dG–dC) in the presence of 70 μM ATP. 
The time-dependent inhibition was then confirmed by setting the preincubation between 
the R525H enzyme and the inhibitor to 0 min or 120 min before the reaction was 
initiated with 2 μg/mL poly(dG–dC) and 70 μM ATP. The reaction time was 5 min to 
confirm the change in the IC50 by setting different preincubation times of the enzyme 
with the inhibitor. 
 
EIF4A3 Enzymatic Activity Assay 
An RNA-dependent ATPase assay for eIF4A3 was also performed using the 
ADP-Glo™ assay system and proteins were prepared by the method described by Ito et 
al [84]. To enhance the ATPase activity of eIF4A3, 150 nM MLN51 was added to 150 
nM eIF4A3 enzyme and 35 μM ATP and 1.5 μg/mL poly-U (MP Biomedicals, Santa 
Ana, CA) were used as the substrates. The reagents were incubated at room temperature 
for 30 min. Detection with ADP-Glo™ was performed as for DDX41. I considered the 
luminescent signals of the reaction without enzyme to indicate 100% inhibitory activity 
and those of the complete reaction mixture to indicate 0% inhibitory activity. Curve 
fitting and the calculation of the IC50 values were performed with GraphPad Prism v.5. 
 
DnaK Enzymatic Activity Assay 
ATPase activity of DnaK was also confirmed using the ADP-Glo™ assay system. The 
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reaction was performed with 24 μM DnaK, 0.5 μM ATP, and test compounds diluted 
with the same assay buffer as DDX41 at room temperature for 40 min. The detection 
with ADP-Glo™, the calculation of activity, and curve fitting were performed as for 
EIF4A3. 
 
Fluorescent Intercalator Displacement Assay 
Poly(dG–dC) (1 µg/mL) and 30 µM candidate hit compound were incubated with 0.1 
µM TO-PRO®-3 stain (Thermo Fisher Scientific) in DDX41 assay buffer for 120 min 
in Greiner 784075 384-well microplates. The displacement activities were detected as 
the fluorescence at an excitation wavelength of 512 nm and an emission wavelength of 
533 nm. I considered the fluorescent signals of the reaction without TO-PRO-3 to 
indicate 100% intercalating activity and those of the complete reaction mixture to 
indicate 0% intercalating activity. 
 
HPLC analysis 
Analytical HPLC was conducted using a corona charged aerosol detector (Thermo 
Fisher Scientific, Waltham, M.A.). An L-column 2 ODS [30 × 2.1 mm I.D., (CERI, 
Tokyo, Japan)] was used at a temperature of 50 °C and a flow rate of 0.5 mL/min. 
Mobile phases A and B under a neutral condition comprised a mixture of 50 mmol/L 
AcONH4, water, and MeCN (1/8/1, v/v/v) and a mixture of 50 mmol/L AcONH4 and 
MeCN (1/9, v/v), respectively. The ratio of mobile phase B was increased linearly from 
5% to 95% over 3 min and 95% over the next 1 min. 
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X-ray structure analysis of the compounds 
All measurements were performed on a Rigaku XtaLAB P200 diffractometer using 
graphite monochromated Cu–Kα radiation. The structure was solved by direct methods 
with software SIR2008  and was refined using full-matrix least-squares on F
2
 with 
SHELXL-2013/4 [85].
 
All non-hydrogen atoms were refined with anisotropic 
displacement parameters. Full crystallographic data have been deposited with the 
Cambridge Crystallographic Data Centre (reference numbers: CCDC 1535690 for 
compound A, CCDC 1535691 for compound B). Copies of the data can be obtained free 
of charge via the following URL: 
http://www.ccdc.cam.ac.uk/Community/Requestastructure/Pages/DataRequest.aspx?. 
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Results 
Activities of DDX41 and Mutants 
The recombinant DDX41, R525H, and E345Q proteins were expressed in E. coli and 
purified through NiNTA and Superdex 200 columns. On SDS-PAGE and western 
blotting, the mutant proteins appeared around the DDX41 band at 83 kDa (Fig. 12A, B). 
A protein mass analysis confirmed the types of proteins contained in the purified 
DDX41, R525H, and E345Q bands. A protein mass analysis revealed that the 
MS-identified peptides covered human DDX41 (Table 5), and DnaK from E. coli was 
one of the proteins included with the purified DDX41 protein (Table 6). A western 
blotting analysis of the purified DDX41 protein detected the DnaK protein with a 
DnaK-specific antibody (Fig. 12C).  
The results of the ATPase activity assay are shown in Fig. 13 and Fig. 14. Both 
DDX41 and R525H displayed double-stranded DNA (dsDNA)-dependent ATPase 
activity, whereas E345Q did not. Analysis of the substrate specificity of DnaK revealed 
that DnaK did not use dsDNA as a substrate. I defined the luminescent signal of the 
reaction without dsDNA as indicating 100% inhibitory activity and that of the complete 
reaction mixture as indicating 0% inhibitory activity, and measured the 
dsDNA-dependent activities of DDX41 and R525H accordingly. 
The apparent Km values for dsDNA and ATP were determined according to the 
Michaelis–Menten equation, and their values are shown in Fig. 14 and Tables 7 and 8, 
respectively. DDX41 and R525H showed the same affinities for both substrates. The 
substrate concentrations under the screening conditions were 70 μM ATP and 0.2 μg/mL 
poly(dG–dC). The concentrations of the substrates were close to the apparent Km 
values to maximize the diversity of screening hits [86] and to maintain the assay quality 
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throughout the screening process. 
 
Identification of Novel R525H Inhibitors with HTS 
A diverse library of more than 500,000 small-molecule compounds (10-compound 
mixture-based library) from the Takeda Pharmaceutical Company Limited was screened 
at a concentration of 3 μM against R525H, as shown in the work flow (Fig. 15A). The 
assay quality was deemed acceptable because the Z′ factor was 0.78 and the 
signal-to-noise ratio was 6.1. The histogram of the primary screening in Fig. 15B shows 
a normal distribution curve with a median value of −0.69 and a standard deviation (SD) 
of 7.8. The hit frequency was 0.5% when the threshold was set at ≥31% of the median + 
3SD inhibitory activity. These primary hit compounds through a process of 
deconvolution were picked and their inhibitory potency for EIF4A3 was tested with the 
ADP-Glo™ assay to eliminate the nonselective compounds. In this step, 12% of the 
initial hits were eliminated and 180 compounds with no activity against eIF4A3 were 
selected (Fig. 16A). All compounds showed the same inhibitory activities for DDX41 
and R525H (Fig. 16B) and none of the compounds showed inhibitory activity for DnaK 
(Fig. 16C). Moreover, in-house database was searched to obtain the compounds which 
showed no activity against other target molecules such as kinases, G protein-coupled 
receptors, and other enzymes and 43 compounds were selected. The presence of false 
positive compounds that interacted as intercalators with poly(dG–dC) was a concern, so 
an intercalator displacement assay using TO-PRO-3 was performed to remove such 
compounds. The threshold was set at 29% of the mean of the low control + 3SD of the 
low control and a total of 13 of the 43 compounds showed displacement activity (Fig. 
16D). The assay to remove the compounds quenching of TO-PRO-3 fluorescence was 
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also performed under the condition without poly(dG-dC) and 4 compounds were 
eliminate. Ultimately, I identified 26 hit candidate compounds, such as compound A 
[ (4E)-N-hydroxy-1-phenyl-2,3-dihydroquinolin-4(1H)-imine, CAS Registry Number: 
10258-02-3] and compound B 
(4-amino-6-((2-amino-1,6-dimethylpyrimidin-4(1H)-ylidene)amino)-1-methyl-2-phenyl
quinolinium chloride hydrochloride or the tautomer, CAS Registry Number: 
115230-55-2), that interacted selectively with DDX41 and R525H from the results 
described above (Fig. 16E). The structures were confirmed by single crystal X-ray 
analysis (Fig. 17,18) and the purities of the compounds were shown to be 95% or more 
by LC-MS. 
 
Characterization of the Hit Compounds 
To understand the mechanism of inhibition, substrate competition assays were 
performed. The rates at which the compounds inhibited R525H were examined under 
the four conditions described in the Materials and Methods. Representative hit 
compounds, exemplified by compound A and compound B, showed the theoretical shift 
in their IC50 values when the poly(dG–dC) concentration was increased (Fig. 19A, B). 
However, the IC50 values for both compounds shifted only slightly when the ATP 
concentration was increased. These results indicate that these hit compounds may be 
competitive inhibitors of DDX41 with respect to the poly(dG-dC) substrate and 
non-competitive inhibitors with respect to the ATP substrate (Fig. 19C, D). Although 
compounds such as DNA intercalators were ruled out by the TO-PRO-3 competition 
assay, there may be other modes of DNA binding besides intercalation, such as minor 
groove binding, major groove binding and electrostatic binding to the backbone. Further 
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analyses would be necessary to draw definitive conclusions on the inhibitory 
mechanism. When the preincubation time (before the reaction was initiated by the 
addition of the substrates) for the enzyme and the test compound was set at 0 min or 120 
min, the inhibitory activities of the compounds remained the same and it was confirmed 
that the compounds are not time-dependent inhibitors (Fig. 19E, F).  
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Discussion 
The results show that the ATPase activities of human DDX41 and R525H are 
dependent on ATP and dsDNA, either poly(dG–dC) or poly(dA–dT). Novel inhibitors of 
DDX41 and R525H were identified with HTS. Two hit compounds identified with 
several assays showed selective inhibitory activities. 
DnaK was present in the purified DDX41 and R525H enzymes, detected with mass 
spectrometry and western blotting. The DnaK protein is a molecular chaperone and 
folding catalyst, with ATPase activity in the presence of ATP [87]. I tried to prepare 
high-purity enzymes by removing the contaminated proteins, such as DnaK, with anion 
exchange column chromatography. However, this caused the aggregation of DDX41. It 
is possible that DnaK assists in the folding of DDX41 in E. coli. The activities of 
DDX41/R525H and DnaK could be differentiated based on their dsDNA-dependent 
ATPase activities because the human E345Q ATPase defective mutant and DnaK 
showed no dsDNA-dependent ATPase activity. Therefore, I set assay conditions in the 
presence or absence of dsDNA to represent the maximum and minimum controls to 
detect the activities of DDX41 and R525H. 
DDX41 may have both ATPase and helicase activities, but no assay for helicase 
activity has yet been reported. The Km values for dsDNA against DDX41 and R525H 
were very similar. I speculate that these values would differ if the enzymes were 
analyzed with helicase activity assays. Pause et al [88] reported that mutants R365Q and 
R365K of eIF4A3, whose position corresponds to the conserved residue R525 in 
DDX41, exhibited dramatic reductions in the helicase activity for dsRNA, but did not 
show a significant difference in ATPase activity. The poly(dG–dC) and poly(dA–dT) 
used in this experiment were purchased from Sigma, and the lengths of these dsDNAs 
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were not accurately characterized. If the sequence of the dsDNA or dsRNA recognized 
by DDX41 is determined and a helicase assay is established, the hypothesis that DDX41 
and R525H have different helicase activities can be tested [89].  
Several compounds were identified with HTS. In parallel with HTS, I developed a 
selectivity assay to verify the specificity of the enzymatic inhibition. The hit compounds, 
compound A and compound B, displayed inhibitory activities with IC50 values of 4.3 
μM and 1.5 μM, respectively, against human R525H mutant under the HTS conditions 
used and no activity for eIF4A3 and DnaK. Although I initially selected EIF4A3 
because of its ready availability, the further selectivity analysis is necessary using 
another helicase with more similar sequences with DDX41. In general, the DNA- or 
RNA-unwinding activities of helicases are dependent on their ATPase activity. 
Therefore, these hit compounds may also inhibit the helicase activity of DDX41 and 
R525H. HTS results suggest that DDX41 is a potential drug target because no inhibitors 
of DDX41 have yet been identified. There may be a prominent binding site for 
small-molecule inhibitors in DDX41 that overlaps the poly(dG–dC)-binding site. The 
crystal structures of the DDX41-bound inhibitors could clarify their mode of inhibition 
and facilitate the optimization of lead compounds. 
It has been reported that DDX41 interacts directly with several proteins including 
STING and TBK1, which is a crucial adaptor molecule for cytoplasmic DNA receptors 
[33]. The silencing of DDX41 expression in murine myeloid dendritic cells led to a 
marked reduction in IFN and proinflammatory cytokine production in response to 
cytosolic DNA [83]. Besides its role in immunity, the human R525H mutation is 
associated with familial MDS and AML. Xenograft experiments with cell lines in which 
DDX41 was knocked down demonstrated DDX41-enhanced tumor growth, but the 
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mechanism behind this is still not understood. I have identified inhibitors of both 
DDX41 and R525H, with which it should be possible to conduct biochemical analyses. 
The clarification of their efficacy in tumor cells, the molecular mechanism of DDX41, 
and the crystal structure of DDX41 when bound to these compounds will have a 
significant impact on research into DDX41. If it is possible to create a DDX41 or 
R525H selective inhibitor by lead generation, the significance of the mutation could be 
clarified. 
In conclusion, my study provides evidence that DDX41 has dsDNA-dependent ATPase 
activity, dependent on poly(dG–dC) or poly(dA–dT), and presents new chemical tools 
for further investigation of the multiple functions of DDX41. 
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Figures and Tables 
 
Figure 12. Analysis of purified enzymes.  
SDS-PAGE of DDX41, R525H, and E345Q stained with Coomassie Blue (A) and a 
western blot probed with an anti-His-tag antibody (B) or anti-DnaK antibody (C). 
DnaK from E. coli was one of the proteins retained in the purified DDX41. 
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Figure 13. Substrate specificities of DDX41, R525H, E345Q, and DnaK. 
The substrate specificities were confirmed with 5 μg/mL poly(dA–dT), poly(dG–dC), 
and poly-U in the presence of 100 μM ATP and 500 nM enzyme. DDX41 (A) and 
R525H (B) showed poly(dA–dT)- or poly(dG–dC)-dependent activities, but E345Q (C) 
and DnaK (D) were not activated by dsDNA. Relative activity values were calculated 
by setting 100% as the activity without dsDNA or dsRNA. Data shown are mean ± SD 
of n = 2 technical replicates and are representative of two independent experiments. WT, 
wild type 
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Figure 14. Determination of the kinetic constants for ATP and dsDNA (poly[dA–dT] 
and poly[dG–dC]) in ATPase reactions with recombinant DDX41 or R525H protein.  
The assay was performed with 5 μg/mL dsDNA and increasing concentrations of ATP 
(A) and (C); or 100 μM ATP and increasing concentrations of dsDNA (B) and (D). Km 
values for poly(dA–dT) and poly(dG–dC) with ATP are shown in Tables 7 and 8, 
respectively. RLU, relative luminescence units. Data shown are mean ± SD of n = 2 
technical replicates and are representative of two independent experiments. 
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Figure 15. Screening cascade and results of primary screening. 
The HTS cascade consisted of the primary screening, profiling assay, hit validation, and 
characterization (A). A diverse library of small compounds from Takeda Pharmaceutical 
Company at a concentration of 3 μM was screened against DDX41, as shown in the 
histogram (B). The hit frequency of the primary screening was 0.5%; hits showed ≥31% 
of the median + 3SD inhibitory activity. 
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Figure 16. Results of profiling assays 
The primary hit compounds were analyzed with a selectivity assay using eIF4A3 (A), 
DDX41 (B), and DnaK (C). An intercalator displacement assay using TO-PRO-3 was 
conducted to remove compounds that interacted as an intercalator with poly(dG–dC) 
(D). The two white circles represent compound A and compound B. The structures of 
compounds A and B are shown in (E). 
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Figure 17. ORTEP of compound A; thermal ellipsoids are drawn at 50% probability.  
Crystal data for (4E)-N-hydroxy-1-phenyl-2,3-dihydroquinolin-4(1H)-imine (compound 
A): C15H14N2O, MW = 238.29; crystal size, 0.18 × 0.17 × 0.06 mm; colorless, block; 
monoclinic, space group C2/c, a = 17.3229(9) Å, b = 8.0063(3) Å, c = 18.7849(9) Å, α 
= γ = 90°, β = 107.059(6)°, V = 2490.7(2) Å3, Z = 8, Dx = 1.271 g/cm3, T = 100 K, μ = 
0.646 mm
−1
, λ = 1.54184 Å, R1 = 0.051, wR2 = 0.154.  
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Figure 18. ORTEP of compound B; thermal ellipsoids are drawn at 50% probability. 
Crystal data for 
4-amino-6-((2-amino-1,6-dimethylpyrimidin-4(1H)-ylidene)amino)-1-methyl-2-phenylq
uinolinium chloride hydrochloride or the tautomer (compound B): 
C22H24N6
2+∙2Cl−∙H2O∙C2H6O, MW = 507.46; crystal size, 0.10 × 0.05 × 0.04 mm; 
colorless, block; triclinic, space group P-1, a = 10.8559(2) Å, b = 11.6852(3) Å, c = 
11.8228(4) Å, α = 118.093(3)°, β = 101.204(2)°, γ = 98.906(2)°, V = 1244.17(7) Å3, Z = 
2, Dx = 1.354 g/cm
3
, T = 100 K, μ = 2.622 mm−1, λ = 1.54184 Å, R1 = 0.040, wR2 = 
0.107. Compound B was crystallized in 1:1:1 complex with H2O and ethanol. 
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Figure 19. Profiling assays of compound A and compound B with R525H. 
The results for compound A are shown in (A), (C), and (E) and those for compound B 
are shown in (B), (D), and (F). Dose–response curves in the presence of 0.2 μg/mL or 
20 μg/mL poly(dG–dC) were determined (A) and (B); the IC50 values of these 
compounds were increased by a high concentration of poly(dG–dC). Dose–response 
curves in the presence of 70 μM or 700 μM ATP were determined (C) and (D); the IC50 
values of these compounds were not changed by a high concentration of ATP. Dose–
response curves were determined by setting the preincubation period for the enzyme and 
inhibitor at 0 min or 120 min before the reaction was initiated with 20 μg/mL poly(dG–
dC) and 70 μM ATP, to confirm the time-dependent inhibition (E) and (F). The x-axes 
indicate the concentration of the compounds and the y-axes indicate % inhibition. Data 
shown are mean ± SD of n = 2 technical replicates and are representative of two 
independent experiments.  
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Table 5. Human proteins identified by mass spectrometric analysis  
 
 
 
 
 
 
 
 
 
 
 
Table 6. Escherichia coli proteins identified using mass spectrometric analysis 
 
Accession Description 
Sequence 
coverage 
Number of 
matched peptides 
MW 
(kDa) 
Q9UJV9 
Probable ATP-dependent RNA 
helicase DDX41 
48.07 32 69.8 
P04264 Keratin, type II cytoskeletal 1 12.42 7 66.0 
P13645 Keratin, type I cytoskeletal 10 6.34 3 58.8 
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 Table 7. Apparent Km values of ATP and poly(dG-dC)
a
  
 
Accession Description 
Sequence 
coverage 
Number of 
matched peptides 
MW 
[kDa] 
A7ZHA4 Chaperone protein DnaK 65.7 34 69.1 
P39451 
Alcohol dehydrogenase, 
propanol-preferring 
55.1 11 35.4 
P17169 
Glucosamine-fructose-6-phosphate 
aminotransferase 
51.0 22 66.9 
P35340 
Alkyl hydroperoxide reductase 
subunit F 
21.9 8 56.1 
A7ZTY0 
Guanosine-5′-triphosphate,3′ 
-diphosphate pyrophosphatase 
17.4 7 54.9 
B7MG22 
Bifunctional polymyxin resistance 
protein ArnA 
14.9 7 74.3 
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a
The numbers in parentheses represent 95% confidence intervals. 
 
 
 
 
 
 
 
 
 
 
Table 8. Apparent Km values of ATP and poly(dA-dT)
a 
Enzyme ATP apparent Km (μM) Poly(dG-dC) apparent Km (μg/mL) 
DDX41 79 (61–96) 0.59 (0.46–0.71) 
R525H 113 (92–133) 0.42 (0.26–0.58) 
Enzyme ATP apparent Km (μM) Poly(dA-dT) apparent Km (μg/mL) 
DDX41 82 (66–97) 0.24 (0.15–0.32) 
R525H 66 (54–79) 0.25 (0.19–0.32) 
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a
The numbers in parentheses represent 95% confidence intervals. 
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General Discussion 
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General discussion 
Drug discovery research can generally be conducted by the flow shown in Fig. 20. 
Developing a new drug from an original idea to its launch is a complex process that can 
take up to 15 years [82, 83]. Fig. 20 indicates the key preclinical stages of the drug 
discovery process from initial target identification and validation, through assay 
development, high throughput screening, hit identification, lead optimization, and 
finally, the selection of a candidate molecule for clinical development. 
My research described in this thesis is positioned at the first stage. Generally, in the 
first stage, molecular, biological, and biochemical analyses are conducted to establish 
the basic knowledge to discover new drugs. The enzyme molecular dynamics can be 
evaluated successfully with some original assay methods and selective inhibitors are 
obtained though HTS. In my research, novel assay methods were established to detect 
PARP14 and DDX41 enzymatic activities. In the research on PARP14, I described the 
identification of potent, selective, and cell-permeable inhibitors through HTS. A strategy 
for creating potential lead compounds could be developed by solving the X-ray 
co-crystal structure of PARP14 with the hit compounds and SAR information. In the 
research on DDX41, the ATPase activities of human DDX41 and R525H were shown to 
be dependent on ATP and dsDNA, either poly(dG–dC) or poly(dA–dT). Novel 
inhibitors of DDX41 and R525H were identified by HTS. The hit compounds identified 
using several assays showed selective inhibitory activities. Therefore, my research 
provides new evidences on the properties of the STAT6 signal-related enzymes, 
PARP14 and DDX41, and presents chemical tools for further investigation of the 
multiple functions of both targets.  
The STAT6 pathway is generally well-characterized as it has been implicated in related 
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to multiple diseases such as inflammation and cancer. There are two primary 
STAT6-mediated cellular pathways, i.e. the canonical and noncanonical pathways. The 
canonical pathway is activated by ligand interaction with IL-4/IL-12 receptors. Signal 
transduction of the canonical pathway results in the expression of GATA3. The 
noncanonical pathway uses a largely different set of proteins within its signaling 
cascade from those of the canonical one. A specific set of proteins including DDX41, 
STING, and TBK1, are responsible for inducing the noncanonical signaling. 
Transduction of this alternative pathway is dependent on the kinds of immune cells and 
ultimately results in cytokine production. Despite extensive validation of these two 
branches of the STAT6 pathway and their associated targets, considerable efforts within 
the pharmaceutical industry and academia have failed to produce therapeutics with 
clinical efficacy. These efforts have primarily adopted target-driven approaches, 
focusing mainly on creating inhibitors against STAT6 dimers and JAK because of their 
central functions within the pathway in the context of immunity. Although a number of 
these inhibitors have been developed, none so far have demonstrated therapeutic utility 
in the clinic. It has been difficult to obtain inhibitors with high potency and selectivity 
against these molecules. Therefore, I considered that PARP14 and DDX41 have 
possibilities as novel drug targets. 
Based on the results of my enzymological research using molecular biological and 
biochemical strategies, the phase of drug discovery research for PARP14 and DDX41 
will move to the lead generation stage and the role of these molecules will be clarified 
using the chemical probes that I obtained.  
Lead compounds that possess higher inhibitory activities against PARP14 and 
appropriate pharmacokinetics might be synthesized based on the information from 
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X-ray co-crystal structures with hit compounds in the future. Moreover, the expression 
differences of target genes such as Gata3 and cytokines secreted by Th2 cells and B 
cells can be evaluated using the hit compounds to determine how PARP14 contributes to 
STAT6 signaling. The effects of these compounds on the differentiation of Th2 cells and 
B cells were also confirmed. In addition to allergy, PARP14 has been shown to promote 
the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 
phosphorylation [62]. Such reports raise the possibility that targeting PARP14 may 
result in the development of effective therapies for inflammatory diseases as well as 
various cancers.  
In the case of DDX41, selective inhibitors of R525H might be created first. It might be 
effective to obtain the crystal structure of both WT and R525H because it provides the 
information to determine the structural differences affecting the compound selectivity. If 
I successfully create selective compounds for R525H mutants, experiments analyzing 
the expression of cytokines such as CCL2 and CCL20 will be conducted with or 
without the tool compounds. As already mentioned in this thesis, the human R525H 
mutation is associated with familial MDS and AML. Xenograft experiments with cell 
lines in which DDX41 is knocked down could be performed to demonstrate 
DDX41-enhanced tumor growth. In order to uncover the underlying mechanism, the 
efficacy of the target could be clarified with tumor cells using R525H selective 
inhibitors. 
This study clarified that PARP14 was present in the common ancestor of all metazoa. 
On the other hand, DDX41 was conserved in metazoa, plants, and fungi. Both 
molecules might play important roles within the organisms from the perspective of the 
cellular evolutionary process. The tool compounds might contribute to analyze these 
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molecules more deeply. 
In summary, it will be possible to conduct functional cell analyses using the putative 
inhibitors that I discovered in this research, which may help elucidate the contribution 
of PARP14 and DDX41 to STAT6 signaling and other functions, respectively. The 
enzymological research described here is a key step for drug discovery. The results can 
be significant for discovering novel drugs against STAT6 related diseases and 
understanding the mechanism of STAT6 signaling. 
 
 
 
Figure 20 The process of drug discovery and development 
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